Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AHFD manufactures vitamin fortified energy bars
The company claims that energy bar utilises the highest quality 100% natural, organic ingredients that are Organic and Kosher certified ingredients. Active X energy bars is available in
The company claims that energy bar utilises the highest quality 100% natural, organic ingredients that are Organic and Kosher certified ingredients. Active X energy bars is available in
MMRF’s Personalized Medicine Initiative has been developed to allow molecular characterization of multiple myeloma patients and thus enforce the development of new, targeted treatments. Onyx is believed to
Under the contract, SRI will carry on with the development of NIAID’s Division of Microbiology and Infectious Diseases (DMID) program that involves translation of basic research into clinical
The patent named ‘Mammalian cell lines for increasing longevity and protein yield from a cell culture’ provides coverage until 2025. It covers improved cell lines of greater longevity,
Following the approval for sNDA, the capsules’ labeling will feature clinical safety and efficacy data for Vancocin in treating currently circulating strains of Clostridium difficile, including the BI/NAP1
The collaboration will help various countries across the globe in making them self-sufficient in the manufacture of vital biopharmaceuticals such as vaccines, insulin and biosimilars, thus reducing the
Kymos plans to take up research activities in a new immunology laboratory that will be opened in the Barcelona Science Park (PCB) in early January 2012, conducting regulatory
The system with dendrimers, is believed to deliver steroids into the targeted cells that cause neuroinflammation damage, which in turn leads to retinitis pigmentosa and can ultimately cause
The company has received funds worth £450,000 from Finance Wales, Acceleris, Welsh Government and Denbighshire County Council, which would support its entry into the next phase of development,
The Phase 1 study involved 32 patients with either acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL), and will determine the maximum tolerated dose (MTD), dose limiting